Accordingly, patients with biochemical recurrence having the lowest PSA levels prior to PSMA PET/CT had the lowest detection rate (55.1%) compared to patients with persistent (75%) or primary prostate cancer (100%). This evidence concerns the gene FOLH1 and prostate carcinoma.